Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 1.19
CLVS's Cash-to-Debt is ranked lower than
78% of the 1078 Companies
in the Global Biotechnology industry.

( Industry Median: 64.02 vs. CLVS: 1.19 )
Ranked among companies with meaningful Cash-to-Debt only.
CLVS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.91  Med: 2.23 Max: No Debt
Current: 1.19
0.91
No Debt
Equity-to-Asset 0.32
CLVS's Equity-to-Asset is ranked lower than
84% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. CLVS: 0.32 )
Ranked among companies with meaningful Equity-to-Asset only.
CLVS' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.32  Med: 0.41 Max: 0.75
Current: 0.32
0.32
0.75
Debt-to-Equity 1.84
CLVS's Debt-to-Equity is ranked lower than
92% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 0.28 vs. CLVS: 1.84 )
Ranked among companies with meaningful Debt-to-Equity only.
CLVS' s Debt-to-Equity Range Over the Past 10 Years
Min: -77.36  Med: 0.93 Max: 4.92
Current: 1.84
-77.36
4.92
Debt-to-EBITDA -2.05
CLVS's Debt-to-EBITDA is ranked lower than
99.99% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 2.04 vs. CLVS: -2.05 )
Ranked among companies with meaningful Debt-to-EBITDA only.
CLVS' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.05  Med: -0.8 Max: -0.75
Current: -2.05
-2.05
-0.75
Piotroski F-Score: 3
Altman Z-Score: -0.87
Beneish M-Score: -0.67
WACC vs ROIC
8.04%
-416.27%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -356.54
CLVS's Operating Margin % is ranked lower than
64% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -113.97 vs. CLVS: -356.54 )
Ranked among companies with meaningful Operating Margin % only.
CLVS' s Operating Margin % Range Over the Past 10 Years
Min: -375835.9  Med: -1132.79 Max: -356.54
Current: -356.54
-375835.9
-356.54
Net Margin % -382.83
CLVS's Net Margin % is ranked lower than
65% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -111.91 vs. CLVS: -382.83 )
Ranked among companies with meaningful Net Margin % only.
CLVS' s Net Margin % Range Over the Past 10 Years
Min: -447611.54  Med: -1174.54 Max: -382.83
Current: -382.83
-447611.54
-382.83
ROE % -89.44
CLVS's ROE % is ranked lower than
71% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -42.82 vs. CLVS: -89.44 )
Ranked among companies with meaningful ROE % only.
CLVS' s ROE % Range Over the Past 10 Years
Min: -235.1  Med: -111.62 Max: -26.78
Current: -89.44
-235.1
-26.78
ROA % -36.09
CLVS's ROA % is ranked lower than
51% of the 1084 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. CLVS: -36.09 )
Ranked among companies with meaningful ROA % only.
CLVS' s ROA % Range Over the Past 10 Years
Min: -144.39  Med: -57.06 Max: -21.25
Current: -36.09
-144.39
-21.25
ROC (Joel Greenblatt) % -3683.00
CLVS's ROC (Joel Greenblatt) % is ranked lower than
76% of the 1036 Companies
in the Global Biotechnology industry.

( Industry Median: -521.46 vs. CLVS: -3683.00 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CLVS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -9748.56  Med: -7990.33 Max: -3683
Current: -3683
-9748.56
-3683
3-Year Revenue Growth Rate 43.20
CLVS's 3-Year Revenue Growth Rate is ranked higher than
87% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. CLVS: 43.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CLVS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 43.2
Current: 43.2
0
43.2
3-Year EBITDA Growth Rate -16.20
CLVS's 3-Year EBITDA Growth Rate is ranked lower than
72% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. CLVS: -16.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CLVS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -51.8  Med: -16.2 Max: 53.4
Current: -16.2
-51.8
53.4
3-Year EPS without NRI Growth Rate -16.00
CLVS's 3-Year EPS without NRI Growth Rate is ranked lower than
72% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 5.70 vs. CLVS: -16.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CLVS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -48.8  Med: -16 Max: 53.1
Current: -16
-48.8
53.1
GuruFocus has detected 3 Warning Signs with Clovis Oncology Inc CLVS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CLVS's 30-Y Financials

Financials (Next Earnings Date: 2018-11-01 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

CLVS Guru Trades in Q3 2017

Columbia Wanger 581,660 sh (New)
Ken Fisher 26,633 sh (New)
Louis Moore Bacon 30,000 sh (+200.00%)
Ron Baron 29,147 sh (+94.12%)
Steven Cohen Sold Out
Joel Greenblatt Sold Out
Leon Cooperman Sold Out
Jim Simons Sold Out
Chuck Royce 50,000 sh (-24.24%)
» More
Q4 2017

CLVS Guru Trades in Q4 2017

Paul Tudor Jones 5,868 sh (New)
Steven Cohen 876,000 sh (New)
Pioneer Investments 52,800 sh (New)
Ken Fisher 47,961 sh (+80.08%)
Chuck Royce 50,000 sh (unchged)
Steven Cohen 268,000 sh (unchged)
Ron Baron Sold Out
Columbia Wanger 514,996 sh (-11.46%)
Louis Moore Bacon 25,000 sh (-16.67%)
» More
Q1 2018

CLVS Guru Trades in Q1 2018

Jim Simons 258,000 sh (New)
Pioneer Investments 199,000 sh (+276.89%)
Steven Cohen 1,155,937 sh (+31.96%)
Ken Fisher 47,961 sh (unchged)
Louis Moore Bacon 25,000 sh (unchged)
Chuck Royce Sold Out
Paul Tudor Jones Sold Out
» More
Q2 2018

CLVS Guru Trades in Q2 2018

Stanley Druckenmiller 482,000 sh (New)
Pioneer Investments 283,300 sh (+42.36%)
Ken Fisher 58,306 sh (+21.57%)
Louis Moore Bacon 25,000 sh (unchged)
Jim Simons Sold Out
Steven Cohen 165,000 sh (-85.73%)
» More
» Details

Insider Trades

Latest Guru Trades with CLVS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2018-06-30 Add 21.57%$42.06 - $62.4 $ 32.38-33%58,306
Ken Fisher 2017-12-31 Add 80.08%$57.69 - $84.58 $ 32.38-54%47,961
Ron Baron 2017-12-31 Sold Out 0.01%$57.69 - $84.58 $ 32.38-54%0
Ron Baron 2017-09-30 Add 94.12%$67.17 - $98.02 $ 32.38-59%29,147
Ken Fisher 2017-09-30 New Buy$67.17 - $98.02 $ 32.38-59%26,633
Leon Cooperman 2017-09-30 Sold Out 0.2%$67.17 - $98.02 $ 32.38-59%0
Joel Greenblatt 2017-09-30 Sold Out $67.17 - $98.02 $ 32.38-59%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:PTLA, TSE:4974, NAS:PBYI, NYSE:XON, SZSE:300294, NAS:ANAB, XKRX:006280, NAS:CRSP, NAS:RARE, SZSE:002653, LSE:GNS, NAS:AKCA, ROCO:4147, NYSE:EBS, NAS:ASND, XKRX:095700, NAS:FOLD, SZSE:002287, XSWX:GALE, NAS:GBT » details
Traded in other countries:C6O.Germany,
Headquarter Location:USA
Clovis Oncology Inc is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets.

Clovis Oncology Inc is operative in the healthcare sector based in the United States. As a pharmaceutical manufacturer, it is focused on developing and commercializing anti-cancer agents. Its suite of product candidates includes Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor for the treatment of non-small cell lung cancer. Rucaparib is an oral inhibitor of poly (ADP-ribose) polymerase (PARP) that is in advanced clinical development for the treatment of ovarian cancer. The company's revenue primarily depends on the sale of Rucaparib in the United States market.

Top Ranked Articles about Clovis Oncology Inc

Recent Analysis Shows KalVista Pharmaceuticals, IZEA, Sonic Automotive, Catabasis Pharmaceuticals, ANI Pharmaceuticals, and Clovis Oncology Market Influences — Renewed Outlook, Key Drivers of Growth
Analysis: Positioning to Benefit within PBF Energy, Callaway Golf, Total System Services, Comcast, The Cheesecake Factory, and Clovis Oncology — Research Highlights Growth, Revenue, and Consolidated Results
Clovis Oncology and Immunomedics Announce Planned Clinical Collaboration to Study Combination Therapies in Metastatic Triple-Negative Breast and Urothelial Cancers
Consolidated Research: 2018 Summary Expectations for Catalent, MGIC Investment, United Rentals, Clovis Oncology, Pure Storage, and Chipotle Mexican Grill — Fundamental Analysis, Key Performance Indications
Thinking about buying or selling Applied Optoelectronics Inc, Bloomin' Brands, Clovis Oncology, Roku or Wayfair?
CORRECTING and REPLACING – Recent Analysis Shows Pure Storage, Catalent, Boyd Gaming, Halozyme Therapeutics, Clovis Oncology, and General Cable Market Influences – Renewed Outlook, Key Drivers of Growth
Recent Analysis Shows Pure Storage, Catalent, Boyd Gaming, Halozyme Therapeutics, Clovis Oncology, and General Cable Market Influences – Renewed Outlook, Key Drivers of Growth

Ratios

vs
industry
vs
history
PB Ratio 5.46
CLVS's PB Ratio is ranked lower than
63% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. CLVS: 5.46 )
Ranked among companies with meaningful PB Ratio only.
CLVS' s PB Ratio Range Over the Past 10 Years
Min: 1.28  Med: 6.61 Max: 18.33
Current: 5.46
1.28
18.33
PS Ratio 21.49
CLVS's PS Ratio is ranked lower than
63% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CLVS: 21.49 )
Ranked among companies with meaningful PS Ratio only.
CLVS' s PS Ratio Range Over the Past 10 Years
Min: 20.97  Med: 102.54 Max: 445.75
Current: 21.49
20.97
445.75
EV-to-EBIT -5.64
CLVS's EV-to-EBIT is ranked lower than
99.99% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.17 vs. CLVS: -5.64 )
Ranked among companies with meaningful EV-to-EBIT only.
CLVS' s EV-to-EBIT Range Over the Past 10 Years
Min: -26  Med: -8.6 Max: -1.4
Current: -5.64
-26
-1.4
EV-to-EBITDA -5.71
CLVS's EV-to-EBITDA is ranked lower than
99.99% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 18.08 vs. CLVS: -5.71 )
Ranked among companies with meaningful EV-to-EBITDA only.
CLVS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -27  Med: -8.7 Max: -1.5
Current: -5.71
-27
-1.5
EV-to-Revenue 20.96
CLVS's EV-to-Revenue is ranked lower than
59% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 13.69 vs. CLVS: 20.96 )
Ranked among companies with meaningful EV-to-Revenue only.
CLVS' s EV-to-Revenue Range Over the Past 10 Years
Min: 16.2  Med: 89.75 Max: 427.7
Current: 20.96
16.2
427.7
Current Ratio 10.03
CLVS's Current Ratio is ranked higher than
77% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. CLVS: 10.03 )
Ranked among companies with meaningful Current Ratio only.
CLVS' s Current Ratio Range Over the Past 10 Years
Min: 0.86  Med: 7.93 Max: 31.09
Current: 10.03
0.86
31.09
Quick Ratio 9.21
CLVS's Quick Ratio is ranked higher than
75% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.18 vs. CLVS: 9.21 )
Ranked among companies with meaningful Quick Ratio only.
CLVS' s Quick Ratio Range Over the Past 10 Years
Min: 0.86  Med: 7.93 Max: 31.09
Current: 9.21
0.86
31.09
Days Inventory 750.76
CLVS's Days Inventory is ranked lower than
98% of the 481 Companies
in the Global Biotechnology industry.

( Industry Median: 125.55 vs. CLVS: 750.76 )
Ranked among companies with meaningful Days Inventory only.
CLVS' s Days Inventory Range Over the Past 10 Years
Min: 427.73  Med: 427.73 Max: 750.76
Current: 750.76
427.73
750.76
Days Sales Outstanding 58.99
CLVS's Days Sales Outstanding is ranked higher than
56% of the 668 Companies
in the Global Biotechnology industry.

( Industry Median: 64.17 vs. CLVS: 58.99 )
Ranked among companies with meaningful Days Sales Outstanding only.
CLVS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 7.53  Med: 40.64 Max: 566.22
Current: 58.99
7.53
566.22
Days Payable 347.99
CLVS's Days Payable is ranked higher than
88% of the 536 Companies
in the Global Biotechnology industry.

( Industry Median: 63.91 vs. CLVS: 347.99 )
Ranked among companies with meaningful Days Payable only.
CLVS' s Days Payable Range Over the Past 10 Years
Min: 347.99  Med: 28684.67 Max: 56898.29
Current: 347.99
347.99
56898.29

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -14.20
CLVS's 3-Year Average Share Buyback Ratio is ranked lower than
52% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -13.40 vs. CLVS: -14.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CLVS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -194.7  Med: -14.2 Max: -4.5
Current: -14.2
-194.7
-4.5

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 63.49
CLVS's Price-to-Net-Cash is ranked lower than
93% of the 613 Companies
in the Global Biotechnology industry.

( Industry Median: 7.29 vs. CLVS: 63.49 )
Ranked among companies with meaningful Price-to-Net-Cash only.
CLVS' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.45  Med: 15.96 Max: 89.16
Current: 63.49
2.45
89.16
Price-to-Net-Current-Asset-Value 15.06
CLVS's Price-to-Net-Current-Asset-Value is ranked lower than
80% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: 6.45 vs. CLVS: 15.06 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CLVS' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.43  Med: 11.93 Max: 43.02
Current: 15.06
2.43
43.02
Price-to-Tangible-Book 8.73
CLVS's Price-to-Tangible-Book is ranked lower than
72% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 5.32 vs. CLVS: 8.73 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CLVS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.39  Med: 11.37 Max: 396.95
Current: 8.73
2.39
396.95
Price-to-Median-PS-Value 0.21
CLVS's Price-to-Median-PS-Value is ranked higher than
91% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 0.92 vs. CLVS: 0.21 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CLVS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.2  Med: 1.05 Max: 3.86
Current: 0.21
0.2
3.86
Earnings Yield (Greenblatt) % -17.64
CLVS's Earnings Yield (Greenblatt) % is ranked lower than
66% of the 1081 Companies
in the Global Biotechnology industry.

( Industry Median: -7.73 vs. CLVS: -17.64 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CLVS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -70.4  Med: -11.6 Max: -3.9
Current: -17.64
-70.4
-3.9

More Statistics

Revenue (TTM) (Mil) $76.13
EPS (TTM) $ -5.69
Beta0.97
Volatility34.50%
52-Week Range $31.19 - 86.26
Shares Outstanding (Mil)52.65

Analyst Estimate

Dec18 Dec19 Dec20 Dec21
Revenue (Mil $) 117 259 410 523
EBIT (Mil $)
EBITDA (Mil $) -314 -220 -155 -100
EPS ($) -6.16 -2.98 -0.33 0.95
EPS without NRI ($) -6.16 -2.98 -0.33 0.95
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 33
Positive ROAN
Positive CFROAN
Higher ROA yoyY
CFROA > ROAN
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}